O Shaughnessy Asset Management LLC Buys 1,030 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

O Shaughnessy Asset Management LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,920 shares of the biopharmaceutical company’s stock after acquiring an additional 1,030 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $6,660,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Eudaimonia Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock valued at $803,000 after purchasing an additional 11 shares during the last quarter. Team Hewins LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 2.5% in the 1st quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock worth $434,000 after acquiring an additional 11 shares in the last quarter. Angeles Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 3.5% in the 1st quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock worth $313,000 after acquiring an additional 11 shares in the last quarter. Drive Wealth Management LLC grew its position in Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 12 shares during the last quarter. Finally, MCF Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on REGN shares. Canaccord Genuity Group restated a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. TD Cowen increased their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday. Cantor Fitzgerald boosted their target price on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the stock a “neutral” rating in a research note on Monday. Piper Sandler increased their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,166.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Finally, Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,074.95.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $1,011.00, for a total value of $836,097.00. Following the completion of the sale, the director now owns 1,382 shares in the company, valued at approximately $1,397,202. The disclosure for this sale can be found here. Insiders sold 65,074 shares of company stock valued at $64,546,123 over the last quarter. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.5 %

Shares of REGN stock traded up $5.29 on Wednesday, hitting $1,060.86. The stock had a trading volume of 448,527 shares, compared to its average volume of 468,061. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $721.51 and a twelve month high of $1,106.16. The company has a fifty day moving average price of $1,028.34 and a two-hundred day moving average price of $974.34. The firm has a market cap of $116.90 billion, a P/E ratio of 31.18, a PEG ratio of 2.22 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The business had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.